The bladder cancer test developer says it will go to court if an unfavourable US reimbursement decision is not reversed.

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer ...

· Tempus AI, Inc. (NASDAQ: TEM) started 2025 announcing the National Launch of its FDA -approved xT CDx Test, a 648-gene next-generation sequencing test for solid tumor profiling, which includes ...

Stellar results in a bladder cancer study have prompted Astellas to raise its peak sales prediction for Pfizer-partnered antibody-drug conjugate Padcev, although its new menopause therapy Veozah ...

Disitamab vedotin is under clinical development by Pfizer and currently in Phase II for Metastatic ... HER2 expressing non-small cell lung cancer, non-muscle invasive bladder cancer (NMIBC), penile ...

Pfizer also has high hopes for PD-1/PD-L1 inhibitor sasanlimab for non-muscle invasive bladder cancer in the CREST study, and CD3xBCMA bispecific Elrexfio (elranatamab) in MagnetisMM-5 as a ...

Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that the first set of abstracts have been released from several studies that will be shared at the American Society ...

Pfizer (PFE) colorectal cancer therapy Braftovi as part of a drug combo indicates a favorable objective response rate in a ...

Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...

The Pfizer Foundation has provided $15 million investment to a three-year initiative to improve the lives of women with breast cancer in Rwanda, Ghana, and Tanzania. The Grant funding will be provided ...

Pfizer Inc. (PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with ...

Pfizer Inc. (NYSE:PFE) will increase its dividend from last year's comparable payment on the 7th of March to $0.43. This will take the annual payment to 6.5% of the stock price, which is above ...